We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tofacitinib: a successful treatment option for SAPHO syndrome.
- Authors
Sarikaya Solak, Sezgi; Yelgen Ilyas, Hande
- Abstract
A 42-year-old woman with synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome experienced relapsing lesions on her palms and soles and severe chest pain. After trying different medications without success, she was prescribed tofacitinib, a JAK inhibitor. Tofacitinib led to complete remission of palmoplantar pustulosis and significant improvement in joint pain. A review of 13 reports found that tofacitinib was effective in treating SAPHO syndrome, with most patients experiencing improvements in skin and joint symptoms. However, there are limitations to consider, such as the use of additional therapies alongside tofacitinib and the relatively short follow-up duration. Longer follow-up periods are needed to determine the long-term efficacy and safety of tofacitinib for SAPHO syndrome. No severe adverse effects were reported in the studies.
- Subjects
TREATMENT effectiveness; IRIDOCYCLITIS; ACNEIFORM eruptions; SYNDROMES
- Publication
International Journal of Dermatology, 2024, Vol 63, Issue 5, p671
- ISSN
0011-9059
- Publication type
Article
- DOI
10.1111/ijd.17075